Free In-Depth Equity Research Report

On December 1st, Sanofi announced the launch of a new 24-count tablet pack of Priftin® (rifapentine) for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older who are at high risk of progression to tuberculosis (TB) disease.

Going forward ... (see research report)


Access Your Sanofi Report Now!